Bernd Schlereth: Mastering Pharmacokinetics and Immunogenicity of bispecific antibodies

Preclinical and clinical data suggest that anti-TNFa and anti-IL-17A dual cytokine inhibition may represent a very promising novel approach for the treatment of inflammatory diseases (e.g. rheumatoid arthritis, psoriasis and psoriatic arthritis) leading to superior efficacy.
Covagen’s FynomAb technology is well suited for the generation of e.g. bi-specific antibody constructs and allowed for the discovery of COVA322, a dual cytokine (TNFa and IL-17A) inhibitor. COVA322 demonstrated synergistic primary pharmacology and IgG-like pharmacokinetics in nonclinical studies.
This presentation will provide special considerations in the pharmacokinetic and immunogenicity testing strategy of bispecific antibody constructs and will provide some case examples.